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ABSTRACT
We report a 35-year-old female receiving natalizumab as monotherapy for multiple sclerosis who subsequently 
developed severe cytomegalovirus gastritis. As cytomegalovirus gastritis has not been previously described dur-
ing natalizumab treatment, we discuss the biological plausibility of this potential association and avenues for fur-
ther study.
INTRODUCTION
Gastrointestinal (GI) infection by cytomegalovirus (CMV) primarily afﬂicts patients who are immunosuppressed, 
occurring in association with transplantation, malignancy, human immunodeﬁciency virus (HIV) infection, and 
chronic steroid usage.1,2 T cell–mediated immunity is essential in restraining CMV replication and reactivation; thus, 
abnormalities of lymphocyte number, function, or tissue distribution may impact patient susceptibility to infection.3 
Treatment with natalizumab, which binds a4-integrins, promotes such an immunocompromised state by blocking 
adhesion interactions required for lymphocyte trafﬁcking, thus perturbing normal immunosurveillance. While 
numerous studies have discussed natalizumab-associated infections of the central nervous system, fewer studies 
have addressed infectious sequelae at other anatomic sites.
CASE REPORT
A 35-year-old woman presented in September 2015 with two weeks of nausea, vomiting, and epigastric pain, with 
no fevers, chills, or GI bleeding. Her past medical history was notable for multiple sclerosis (MS) diagnosed in 2012, 
no prior history of GI disease, and no history of recurrent or opportunistic infections that would suggest immuno-
deﬁciency. Her medications included ergocalciferol, dosed at 50,000 units per week since October 2013, and nata-
lizumab, dosed at 300 mg every 4 weeks since February 2015; she denied use of alcohol and nonsteroidal anti-
inﬂammatory drugs. The patient’s only prior MS therapy was a 6-month trial of dimethyl fumarate started 
December 2013, with no prior treatment with steroids.
On physical examination, the patient was in no apparent distress and exhibited normal vital signs. Abdominal exam 
showed a non-tender, non-distended abdomen with normal bowel sounds and no palpable masses. Complete 
blood count showed a white blood cell count of 4,900/mL (absolute neutrophil and lymphocyte counts were 1,700/
mL and 2,710/mL, respectively), hemoglobin 10.5 g/dL, and platelet count 168,000/mL. Basic chemistry, hepatic 
function, lipase, and coagulation testing were normal. The patient was HIV-negative, and periodic John
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Cunningham (JC) virus serology testing since starting natali-
zumab was negative. Immunoglobulin and cortisol levels, as
well as counts of CD4þ and CD8þ T lymphocytes, were not
assessed. Barium upper GI ﬂuoroscopy demonstrated no
esophageal dilatation or stricture, hiatal hernia, reﬂux, or
ulceration of the esophagus or duodenum. Helical computed
tomography scans of abdomen and pelvis with intravenous
contrast were unremarkable.
Upper GI endoscopy revealed severe inﬂammation of the
entire examined stomach, with mucosal erosions and ery-
thema and without ulceration or mass lesions (Figure 1). Cold
forceps biopsies of the gastric antral mucosa were obtained
for histopathologic analysis. Microscopic examination of he-
matoxylin and eosin-stained tissue showed a chronic inﬂam-
matory inﬁltrate and nuclear enlargement of the glandular
epithelial cells consistent with reactive changes (Figure 2).
Occasional epithelial cell nuclei showed prominent nucleoli
and possible intranuclear inclusions. Immunostaining for CMV
was positive, while it was negative for herpes simplex virus
and Helicobacter pylori (Figure 3). Rapid urease testing of the
biopsy tissue was negative. On the basis of these ﬁndings, a
ﬁnal diagnosis of severe chronic active CMV gastritis was
rendered.
The patient completed a 3-week course of valganciclovir,
dosed at 900 mg twice per day. She reported complete re-
solution of her symptoms on follow-up with her infectious
disease physician 1 week after ﬁnishing treatment. Due to
her clinical improvement, the patient declined repeat en-
doscopy. Natalizumab was continued as her MS symptoms
were well-controlled; she has continued follow-up with her
neurologist approximately every 3 months and has denied
recurrence of her GI symptoms.
DISCUSSION
CMV has a broad cellular tropism and can cause disease in
nearly any organ; within the GI tract, the colon and stomach
are the most commonly affected sites.1,4 Deﬁnitive diagnosis
of CMV gastritis relies on endoscopy and biopsy. Grossly,
mucosal erosion and ulceration may be observed, with hemor-
rhage, obstruction, or perforation seen in more severe cases.
Unusual tissue morphologies of CMV gastritis, with polypoid
or pseudotumoral appearance on endoscopy, have been
described.5,6 Microscopically, infected cells may show cyto-
megaly and intracellular viral inclusions with a surrounding
clear zone ("owl’s eye" inclusions).2,7
CMV gastritis is a rare condition, with approximately 110 cases
described in the literature. Presenting symptoms are gener-
ally nonspeciﬁc, including nausea, vomiting, and epigastric
pain, although several unique presentations have been
described, including protein-losing gastropathy with general-
ized edema, postural epigastric pain, chronic dysmotility, and
Figure 1. Upper GI endoscopy demonstrating severe inﬂammation of the
(A) body and (B) antrum of the stomach, with signiﬁcant erythema, ero-
sions, and friability of the involvedmucosa.
Figure 2. Hematoxylin and eosin staining of gastric antrum tissue demon-
strating severe chronic mucosal inﬂammation and occasional enlarged
cells with prominent intracellular inclusions (arrowheads).
Figure 3. Immunohistochemical staining for CMV shows strong nuclear
reactivity among the enlarged cells.
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gastrocolic ﬁstula formation.8-11 The majority of reported
patients were immunocompromised, although several cases
in immunocompetent patients have been described.8,12 CMV
gastritis is typically self-limited and can be managed suppor-
tively in healthy patients, but antiviral treatment was fre-
quently initiated in the reported cases if patients were
immunosuppressed or had severe or persistent disease.2
Complete recovery was often achieved with resolution of the
pathologic endoscopic ﬁndings, though notably adult cases
of protein-losing gastropathy showed poorer prognosis than
their pediatric counterparts.8
Natalizumab has primarily been associated with progressive
multifocal leukoencephalopathy secondary to JC virus reacti-
vation.13 Consequently, clinical and laboratory assessment of
patient immune status, including total leukocyte and T-lym-
phocyte counts, history of opportunistic infection and prior
immunosuppressive therapy, and periodic JC virus serologic
screening have been recommended for patients taking this
medication.14,15 Other atypical infections, including herpes
simplex and varicella zoster virus encephalitis and meningitis,
as well as CMV colitis, have also been described.16,17 Notably,
CMV colitis has also been reported with the use of vedolizu-
mab, an a4b 7-integrin speciﬁc antibody used to treat inﬂam-
matory bowel disease.18
We hypothesize that CMV gastritis and colitis in patients tak-
ing natalizumab or vedolizumab share a common pathogene-
sis, whereby lymphocyte a4-integrin blockade disrupts
normal mucosal immunosurveillance. Consistently, the cell ad-
hesion molecule MAdCAM-1, which binds a4b 7-integrins, is
expressed by gut endothelial cells, particularly during inﬂam-
mation.19 Human studies and mouse models of H. pylori gastri-
tis have demonstrated dense lymphocytic inﬁltration of
MAdCAM-1–positive tissue foci, implicating this receptor in
recruiting circulating lymphocytes into the gastric mucosa.19,20
More studies, however, are necessary to solidify the connec-
tion between CMV gastritis and natalizumab; given the rarity
of this condition, accrual of greater numbers of natalizumab-
treated patients will likely be necessary. Detailed immuno-
logic workup will be particularly helpful in excluding other
causes of immunodeﬁciency. Finally, animal models of viral GI
infection in the setting of integrin blockade may provide im-
portant proof-of-principle and pathophysiologic insights to
how natalizumab impacts susceptibility to CMVGI infection.
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